Reports Q3 revenue $175.4M, consensus $172.35M. “We are encouraged by CAPLYTA’s strong growth trajectory in the third quarter and look forward to further growth in the remainder of 2024 and beyond. We are on track to submit our sNDA for the adjunctive treatment of MDD later this year and our commercial team is actively preparing for a potential launch in 2025,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular (ITCI) Therapies.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- ITCI Upcoming Earnings Report: What to Expect?
- Intra-Cellular price target raised to $95 from $92 at Morgan Stanley
- Intra-Cellular announces presentations at 2024 ECNP Congress
- Broadcom AI results fail to enthuse the Street: Morning Buzz
- Piper upgrades Intra-Cellular on potential in major depressive disorder